US009856287B2

(12) **United States Patent**
Shultz et al.

(10) **Patent No.: US 9,856,287 B2**
(45) **Date of Patent: *Jan. 2, 2018**

(54) **REFOLDING PROTEINS USING A CHEMICALLY CONTROLLED REDOX STATE**

(71) Applicant: **AMGEN INC.**, Thousand Oaks, CA (US)

(72) Inventors: **Joseph Edward Shultz**, Binningen (CH); **Roger Hart**, Needham, MA (US); **Ronald Nixon Keener, III**, Newbury Park, CA (US)

(73) Assignee: **Amgen Inc.**, Thousand Oaks, CA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **15/422,327**

(22) Filed: **Feb. 1, 2017**

(65) **Prior Publication Data**

US 2017/0145049 A1 May 25, 2017

Related U.S. Application Data

(60) Continuation of application No. 14/793,590, filed on Jul. 7, 2015, which is a continuation of application No. 14/611,037, filed on Jan. 30, 2015, which is a division of application No. 12/820,087, filed on Jun. 21, 2010, now Pat. No. 8,952,138.

(60) Provisional application No. 61/219,257, filed on Jun. 22, 2009.

(51) **Int. Cl.**

C07K 14/00	(2006.01)
C07K 1/113	(2006.01)
C07K 1/14	(2006.01)
C07K 16/00	(2006.01)

(52) **U.S. Cl.**

CPC ***C07K 1/1136*** (2013.01); ***C07K 1/1133*** (2013.01); ***C07K 1/14*** (2013.01); ***C07K 14/00*** (2013.01); ***C07K 16/00*** (2013.01); *C07K 2319/30* (2013.01)

(58) **Field of Classification Search**

None

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,237,224	A	12/1980	Cohen et al.
4,468,454	A	8/1984	Cohen et al.
4,468,464	A	8/1984	Cohen et al.
4,740,470	A	4/1988	Cohen et al.
4,810,643	A	3/1989	Souza
5,466,377	A	11/1995	Grandics et al.
5,663,304	A	9/1997	Builder et al.
5,849,883	A	12/1998	Boone
5,922,846	A	7/1999	Cerletti et al.
6,660,843	B1	12/2003	Feige et al.
6,808,902	B1	10/2004	Treuheit et al.
6,972,327	B1	12/2005	Madani et al.
7,138,370	B2	11/2006	Oliner et al.
7,435,804	B2	10/2008	Kordyum et al.
7,442,778	B2	10/2008	Gegg et al.
7,511,012	B2	3/2009	Han et al.
7,723,490	B2	5/2010	Treuheit et al.
8,906,648	B2	12/2014	Butler et al.
8,940,878	B2	1/2015	Shultz et al.
8,952,138	B2	2/2015	Shultz et al.
9,090,684	B2	7/2015	Borrass et al.
9,200,030	B2	12/2015	Pizarro et al.
2005/0209441	A1	9/2005	Lile
2006/0228329	A1	10/2006	Brady et al.
2007/0238860	A1	10/2007	Schlegl
2008/0214795	A1	9/2008	Ramanan et al.
2008/0260674	A1	10/2008	Dietrich et al.
2008/0260684	A1	10/2008	Dietrich et al.
2010/0267936	A1	10/2010	Treuheit et al.

FOREIGN PATENT DOCUMENTS

CA	2614820	A1	1/2007
CN	1295580	A	5/2001
DE	10-2005-033250	A1	1/2007
DE	2005/033250	A1	1/2007
EP	0 336 641	B1	10/1989
EP	0 657 466	A1	6/1995
EP	1 845 103	A1	10/2007
EP	1845103	A1	5/2015
WO	WO 84/03711		9/1984
WO	WO 88/08003		10/1988
WO	WO 89/10932		11/1989
WO	1992/004382	A1	3/1992

(Continued)

OTHER PUBLICATIONS

United States Patent and Trademark Office Before the Patent Trial and Appeal Board. (Feb. 17, 2017). Decision Granting Institution of Inter Partes Review 37 C.F.R. § 42.108: *Apotex Inc. and Apotex Corp.* Petitioner v. *Amgen Inc. and Amgen Manufacturing Limited*, Patent Owner (Case IPR2016-01542, U.S. Pat. No. 8,952,138 B2), pp. 1-35.

Unites States District Court for the Southern District of Florida. (Dec. 11, 2015). Document 77: *Amgen Inc. and Amgen Manufacturing Limited*, Plaintiffs, v. *Apotex Inc. and Apotex Corp.*, Defendants (Case No. 15-cv-61631-JIC/BSS), pp. 1-23.

Unites States District Court for the Southern District of Florida. (Dec. 11, 2015). Document 77-4: Exhibit 4, *Amgen Inc. and Amgen Manufacturing Limited*, Plaintiffs, v. *Apotex Inc. and Apotex Corp.*, Defendants (Case No. 15-cv-61631-JIC/BSS), pp. 1-16.

(Continued)

Primary Examiner — Yunsoo Kim

(74) *Attorney, Agent, or Firm* — Raymond M. Doss

(57) **ABSTRACT**

A method of refolding proteins expressed in non-mammalian cells present in concentrations of 2.0 g/L or higher is disclosed. The method comprises identifying the thiol pair ratio and the redox buffer strength to achieve conditions under which efficient folding at concentrations of 2.0 g/L or higher is achieved and can be employed over a range of volumes, including commercial scale.

30 Claims, 8 Drawing Sheets